List of Excipients in Branded Drug AUVI-Q

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	AUVI-Q	auvi-q	51662-1661	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA HealthFirst	AUVI-Q	auvi-q	51662-1661	SODIUM BISULFITE
HF Acquisition Co LLC DBA HealthFirst	AUVI-Q	auvi-q	51662-1661	SODIUM CHLORIDE
HF Acquisition Co LLC DBA HealthFirst	AUVI-Q	auvi-q	51662-1661	WATER
HF Acquisition Co LLC DBA HealthFirst	AUVI-Q	auvi-q	51662-1662	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA HealthFirst	AUVI-Q	auvi-q	51662-1662	SODIUM BISULFITE
HF Acquisition Co LLC DBA HealthFirst	AUVI-Q	auvi-q	51662-1662	SODIUM CHLORIDE

AUVI-Q Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

AUVI-Q’s excipient strategy is intentionally narrow: a sterile aqueous epinephrine formulation with sodium chloride for tonicity adjustment, sodium metabisulfite for oxidation control, hydrochloric acid for pH adjustment, and water for injection. The commercial value sits less in the excipients themselves than in their integration with a compact, voice-guided auto-injector, multiple dose strengths, and a formulation that supports rapid emergency use.

The main opportunities are sulfite-tolerant stability, lower-cost manufacturing, pediatric and high-dose presentations, device-compatible formulation improvements, and differentiated delivery systems. The principal technical constraint is epinephrine oxidation, which limits the range of viable excipients and packaging conditions.

What excipients are used in AUVI-Q?

AUVI-Q contains epinephrine in a sterile aqueous solution. The FDA prescribing information identifies the inactive ingredients as sodium chloride, sodium metabisulfite, hydrochloric acid, and water for injection.[1]

Component	Function in AUVI-Q	Commercial or technical relevance
Sodium chloride	Adjusts tonicity	Supports physiological compatibility and injection performance
Sodium metabisulfite	Antioxidant	Helps limit epinephrine oxidation and discoloration
Hydrochloric acid	pH adjustment	Controls formulation pH and chemical stability
Water for injection	Vehicle	Provides the sterile injectable medium

AUVI-Q uses epinephrine concentrations corresponding to 0.1 mg, 0.15 mg, 0.3 mg, and 0.5 mg delivered doses. The 0.1 mg presentation is intended for smaller children, while the 0.5 mg presentation addresses patients requiring a higher epinephrine dose.[1,2]

Why is sodium metabisulfite used?

Epinephrine is susceptible to oxidation. Oxidative degradation can produce adrenochrome and related degradation products, which may cause pink or brown discoloration and reduce potency. Sodium metabisulfite functions as an oxygen-scavenging antioxidant in the formulation.

The FDA labeling warns that sulfite sensitivity can occur, but states that the presence of a sulfite should not deter administration of epinephrine in a life-threatening allergic reaction.[1] This creates a formulation tradeoff:

• Sulfite improves chemical stability.
• Sulfite introduces labeling and hypersensitivity concerns.
• Removing sulfite could create a meaningful differentiation opportunity, but only if stability can be maintained through pH control, oxygen reduction, packaging, and device design.

How does AUVI-Q’s formulation compare with EpiPen?

AUVI-Q and EpiPen use the same active pharmaceutical ingredient, epinephrine, but compete through device design, dose options, usability, and supply reliability rather than major excipient differentiation.

Attribute	AUVI-Q	EpiPen and authorized generic
Active ingredient	Epinephrine	Epinephrine
Primary delivery system	Compact auto-injector with voice guidance	Conventional auto-injector
Common doses	0.1 mg, 0.15 mg, 0.3 mg, 0.5 mg	Typically 0.15 mg and 0.3 mg; availability varies by product
Sulfite position	Sodium metabisulfite is listed in labeling	Sulfite-containing epinephrine products are also common
Main differentiation	Human-factors design, compact size, dose range	Brand recognition, broad pharmacy presence, generic competition
Excipient moat	Limited as a standalone asset	Limited as a standalone asset
Device and use-related moat	More commercially significant	Strong legacy position

The key strategic point is that an excipient change alone is unlikely to displace EpiPen. A competing product would need a combined advantage in stability, usability, price, availability, or dosing.

What formulation patents protect AUVI-Q?

AUVI-Q’s defensibility is likely concentrated in the combination of formulation, container closure, autoinjector mechanics, electronics, software, voice prompts, dose delivery, and manufacturing controls. Excipient composition by itself is a relatively narrow protection category because sodium chloride, sulfite antioxidants, hydrochloric acid, and water for injection are conventional pharmaceutical ingredients.

Potentially valuable claim categories include:

1. A stable epinephrine formulation with defined pH, antioxidant concentration, and impurity limits.
2. A prefilled cartridge or syringe compatible with the AUVI-Q delivery mechanism.
3. Oxygen-reduced filling, sealing, or storage conditions.
4. Device geometry that controls needle deployment and dose delivery.
5. Audio instructions linked to device activation.
6. Dose-specific device configurations for infants, children, and adults.
7. Packaging that protects against light, oxygen, moisture, and mechanical damage.
8. Manufacturing methods that reduce oxidation or particulate formation.

A complete current patent list, expiration analysis, and Orange Book determination requires a live review of FDA and USPTO records. The FDA product label establishes the formulation and approved presentations but does not by itself establish the full patent estate.[1]

How strong is the AUVI-Q patent estate?

The estate is stronger when claims cover the integrated product rather than the excipient list. A conventional epinephrine solution with sodium metabisulfite is vulnerable to design-around strategies. A tightly claimed combination of formulation parameters, sterile cartridge, device architecture, and user interface is harder to reproduce without infringement risk.

The relative strength of each category is:

Protection category	Relative strength	Reason
Conventional excipient selection	Low	Common ingredients and predictable functions
Narrow pH or concentration range	Moderate	May support stability claims if supported by data
Oxygen-control and packaging process	Moderate	Can create manufacturing and validation barriers
Prefilled delivery container	Moderate to high	Device compatibility can constrain alternatives
Voice-guided autoinjector	High if claims remain enforceable	Combines mechanical and electronic elements
Pediatric dose architecture	Moderate	Can support product differentiation and lifecycle management
Manufacturing know-how	Moderate	May be difficult to detect and challenge directly

What excipient strategy could improve AUVI-Q?

Sulfite-reduced or sulfite-free epinephrine

A sulfite-free product would address a recurring concern among patients and clinicians, even though the FDA considers the risk-benefit profile of epinephrine favorable in anaphylaxis.[1] The commercial case would depend on proving equivalent or better stability during long-term storage, temperature excursions, transport, and repeated handling.

Possible approaches include:

• Lower oxygen exposure during compounding and filling.
• Nitrogen or inert-gas headspace control.
• Improved container closure integrity.
• Light-protective packaging.
• Lower-permeability cartridge materials.
• Optimized pH.
• Alternative antioxidants compatible with injectable use.
• Combination antioxidant systems.

A sulfite-free claim could support premium pricing, but the product would face a high regulatory burden. The sponsor would need to establish chemical stability, particulate control, sterility assurance, container compatibility, extractables and leachables, and device performance.

Alternative antioxidant systems

Potential antioxidants must be evaluated for injectable safety, compatibility with epinephrine, pH effects, toxicology, and regulatory precedent. The opportunity is technically attractive but commercially uncertain because sodium metabisulfite is inexpensive, familiar, and already accepted in epinephrine injection products.

The best opportunity may be a lower-sulfite formulation rather than complete elimination. A reduced-antioxidant formulation could preserve stability while narrowing the sulfite exposure issue, although the clinical and labeling benefit would need to be meaningful.

Excipient and device co-optimization

For AUVI-Q, formulation development cannot be separated from the delivery system. The formulation must remain stable inside the cartridge or syringe, maintain viscosity suitable for injection, avoid clogging or precipitation, and deliver the labeled dose across the product shelf life.

The most commercially useful development program would measure:

• Epinephrine potency.
• Adrenochrome and related oxidative degradants.
• Solution color.
• Particulate matter.
• pH drift.
• Delivered volume and dose.
• Needle and cartridge compatibility.
• Stability after temperature cycling.
• Performance after mechanical shock and vibration.

What commercial opportunities exist for AUVI-Q excipients?

Pediatric and infant dosing

The 0.1 mg presentation provides a lifecycle-management opportunity in infants and smaller children. A dedicated low-dose product can reduce dose-selection uncertainty and create institutional demand from pediatricians, allergists, schools, and emergency preparedness programs.

The commercial advantage is not an excipient innovation alone. It is the combination of dose precision, device usability, and reduced risk of selecting an inappropriate strength.

Higher-dose epinephrine delivery

The 0.5 mg dose expands the addressable population among larger adolescents and adults. Some professional guidance has discussed weight-based dosing and the limitations of fixed-dose auto-injectors, although prescribing decisions remain product- and patient-specific.[3]

A higher-dose presentation creates opportunities in:

• Adult allergy clinics.
• Emergency preparedness programs.
• Food-service and hospitality settings.
• Outdoor and occupational safety markets.
• Hospitals and ambulances.
• Patients with high body weight or severe recurrent anaphylaxis.

Institutional and public-access markets

AUVI-Q’s compact design and voice prompts can support deployment where trained medical personnel are not immediately available. Potential customers include schools, universities, airlines, restaurants, camps, workplaces, and public venues.

For institutional buyers, the relevant product attributes are:

• Simple activation.
• Clear audible instructions.
• Shelf-life reliability.
• Low training burden.
• Device readiness.
• Replacement and inventory programs.
• Insurance and reimbursement access.

Licensing opportunities

The most plausible licensing targets are technologies that improve stability or delivery rather than commodity excipients. Potential partners include:

• Injectable antioxidant developers.
• Low-oxygen filling specialists.
• Prefilled syringe and cartridge manufacturers.
• Autoinjector platform companies.
• Pediatric drug-delivery developers.
• Packaging companies with high-barrier sterile systems.
• Digital adherence and emergency-response companies.

The commercial structure could involve an exclusive formulation license, a device co-development agreement, a regional commercialization license, or a supply agreement for a proprietary cartridge or container closure.

AUVI-Q’s commercial rights have changed over time. The product was originally associated with Intelliject and later commercialized through Sanofi before rights returned to Kaleo, which relaunched the product in the United States.[4,5] Any new licensing analysis should distinguish product rights, device rights, formulation rights, and regional distribution rights.

What FDA regulatory status applies to AUVI-Q?

AUVI-Q is an FDA-approved epinephrine auto-injector regulated through a new drug application. FDA approval covers the drug-device combination, including the formulation, dose strengths, delivery mechanism, labeling, and manufacturing controls.[1,2]

An excipient change could require different regulatory treatment depending on its scope:

Change	Likely regulatory issue
Change in sodium chloride level	Formulation comparability and safety
Reduction or removal of sulfite	Stability, impurity profile, labeling, and clinical bridging
New antioxidant	Safety qualification and compatibility
New container material	Extractables, leachables, stability, and device performance
New cartridge or syringe	Combination-product change control
New dose strength	Dose justification, human factors, and labeling
New manufacturing process	Process validation and comparability

A significant excipient change would generally require an FDA supplement or a new regulatory submission, depending on the product and the extent of the change. The sponsor would need to demonstrate that the modified product remains equivalent in quality, safety, performance, and labeled dose delivery.

Are there biosimilar risks for AUVI-Q?

No. AUVI-Q contains a chemically synthesized small-molecule drug, epinephrine. Biosimilar competition under the Public Health Service Act does not apply.

Competitive risk comes from:

• Generic or authorized-generic epinephrine auto-injectors.
• New branded auto-injectors.
• Prefilled syringes.
• Intranasal epinephrine.
• Hospital and emergency-use presentations.
• Potential alternative delivery systems.

The most important emerging technology risk is intranasal epinephrine. Neffy, an intranasal epinephrine product, was approved by the FDA in 2024 for certain patients with anaphylaxis.[6] A needle-free option could compete directly on convenience, portability, and administration by untrained users. It does not eliminate the need for injectable rescue products, but it changes the commercial value proposition for patients who avoid or delay injections.

What generic entry risks exist for AUVI-Q?

Generic entry risk depends on whether a challenger can reproduce the labeled drug performance and obtain a legally substitutable product. The active ingredient is old and chemically straightforward. The harder barriers are:

• Auto-injector engineering.
• Dose accuracy.
• Human-factors validation.
• Device reliability.
• Sterile filling.
• Cartridge compatibility.
• Stability over shelf life.
• Patent claims covering device and formulation combinations.
• FDA requirements for combination-product performance.

A challenger could avoid some intellectual property through a different device architecture. That design-around route would reduce dependence on AUVI-Q’s specific voice-guided system but could produce a less differentiated product.

What patent litigation or Paragraph IV challenges affect AUVI-Q?

Paragraph IV risk is most relevant to patents listed for the approved drug product and associated delivery system. A challenger would need to identify listed patents, certify invalidity, noninfringement, or unenforceability, and satisfy FDA requirements for an abbreviated application.

For AUVI-Q, the practical litigation issues would likely center on:

• Whether claims cover the entire combination product.
• Whether a rival device uses materially different mechanics.
• Whether formulation claims are narrow enough to avoid prior art.
• Whether method-of-use claims cover administration instructions.
• Whether patents are properly listed for the relevant NDA.
• Whether a generic product can obtain substitutability without copying the commercial device.

The FDA Orange Book should be reviewed for current listings tied to the applicable AUVI-Q NDA. Device and software patents may not all appear in the Orange Book, so an Orange Book review alone will not capture the complete freedom-to-operate landscape.

How does AUVI-Q compare with intranasal epinephrine?

Issue	AUVI-Q	Intranasal epinephrine
Administration	Injection	Needle-free nasal delivery
Main user benefit	Guided, rapid injection	Avoids needles and injection technique
Formulation challenge	Oxidation and device compatibility	Nasal absorption, dose consistency, mucosal variability
Excipient opportunity	Antioxidant and packaging optimization	Permeation, viscosity, and nasal residence-time systems
Patent focus	Autoinjector, cartridge, formulation, voice guidance	Nasal formulation, device, dose delivery, absorption
Main commercial risk	Generic auto-injectors and new injectables	Patient and caregiver migration to needle-free products

AUVI-Q retains advantages where injectable delivery is preferred, where nasal administration is unsuitable, or where clinicians want a familiar epinephrine route. Intranasal products may capture patients who delay use because of needle anxiety or device complexity.

What is the revenue exposure to excipient changes?

Excipient changes could affect revenue in two directions. A sulfite-free or reduced-sulfite formulation could support premium pricing and patient segmentation. A lower-cost formulation or simplified cartridge could improve gross margin and public-access affordability.

The largest commercial risks are regulatory delay, stability failures, device incompatibility, and inventory disruption during conversion. Because epinephrine products are emergency medicines, supply continuity is commercially important. A formulation change that requires parallel inventories, new packaging, or a temporary manufacturing shutdown could offset the value of the innovation.

Key Takeaways

• AUVI-Q uses sodium chloride, sodium metabisulfite, hydrochloric acid, and water for injection.
• Sodium metabisulfite is the central excipient from a stability and product-positioning perspective.
• A sulfite-free or reduced-sulfite formulation is the clearest excipient-led differentiation opportunity.
• The strongest intellectual property is likely to arise from the integrated formulation, cartridge, autoinjector, electronics, and manufacturing process.
• Pediatric 0.1 mg and adult 0.5 mg presentations expand lifecycle and market-segmentation opportunities.
• Biosimilars are not a risk because epinephrine is a small molecule.
• Generic auto-injectors, new branded devices, and intranasal epinephrine are the main competitive threats.
• A complete patent-expiration and Paragraph IV analysis requires review of current FDA Orange Book and USPTO records, including device-related patents outside the Orange Book.

FAQs

Can AUVI-Q be reformulated without sodium metabisulfite?

Yes, but the sponsor would need to establish adequate epinephrine stability, impurity control, sterility, packaging compatibility, and device performance. Removing sulfite would be a major formulation change rather than a simple excipient substitution.

Does sodium metabisulfite make AUVI-Q unsafe for patients with sulfite sensitivity?

The FDA labeling recognizes sulfite sensitivity but states that epinephrine should still be administered for life-threatening allergic reactions. The emergency benefit generally outweighs the sulfite-related concern in anaphylaxis.[1]

Is AUVI-Q’s compact size protected by patents?

Potentially, but compactness alone is unlikely to define the full legal protection. Relevant claims may cover device geometry, cartridge placement, needle deployment, dose delivery, electronics, voice instructions, and housing design.

Could an excipient supplier license technology to Kaleo?

Yes. The most valuable licensing targets would involve oxidation control, low-oxygen filling, high-barrier sterile packaging, cartridge compatibility, or alternative antioxidants with injectable safety support.

Will intranasal epinephrine eliminate the market for AUVI-Q?

No. It creates direct competitive pressure but does not eliminate injectable epinephrine demand. Route preference, patient age, nasal suitability, clinical practice, insurance coverage, and product availability will determine substitution.

References

1. U.S. Food and Drug Administration. (2023). AUVI-Q prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2012). AUVI-Q approval package and product information. https://www.accessdata.fda.gov
3. Shaker, M. S., Wallace, D. V., Golden, D. B. K., et al. (2023). Anaphylaxis: A 2023 practice parameter update. Annals of Allergy, Asthma & Immunology, 130(1), 1-58.
4. Sanofi. (2017). Sanofi returns U.S. rights for Auvi-Q to Kaleo. https://www.sanofi.com
5. Kaleo, Inc. (2017). Kaleo announces return of AUVI-Q to the U.S. market. https://kaleo.com
6. U.S. Food and Drug Administration. (2024). FDA approves first epinephrine nasal spray for emergency treatment of allergic reactions. https://www.fda.gov